



List of guidance from ECDC and recent publications on COVID-19

COVID-19 Digest
24 February 2022

ECDC Outputs

Recent publications

Considerations for the use of antibody tests for SARS-CoV-2, first update Technical report – 10 Feb [Read more »](#)

COVID-19 vaccine effectiveness in adolescents aged 12-17 years and interim public health considerations for administration of a booster dose Technical report – 08 Feb [Read more »](#)

Considerations for the use of face masks in the community in the context of the SARS-CoV-2 Omicron variant of concern Technical report – 07 Feb [Read more »](#)

Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA Technical report – 31 Jan [Read more »](#)

Guidance on ending the isolation period for people with COVID-19, third update Technical report – 28 Jan [Read more »](#)

Assessment of the further spread and potential impact of the SARS-CoV-2 Omicron variant of concern in the EU/EEA, 19th update Risk Assessment – 27 Jan [Read more »](#)

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update Technical report – 20 Jan [Read more »](#)

Situation updates on COVID-19

COVID-19 situation update for the EU/EEA: Includes an update on the number of cases and deaths and geographical distribution of 14-day notification rates for the EU/EEA. [Read more »](#)

COVID-19 situation update worldwide: Includes an update on the number of cases and deaths and geographical distribution of 14-day notification rates worldwide. [Read more »](#)

COVID-19 country overview: Provides an overview of the evolving epidemiological situation for the EU/EEA (including case/death notification rates, testing rates, test positivity, hospital and ICU occupancy/capacity per country, vaccination uptake at EU/EEA and country level). [Read more »](#)

Situation dashboard: Interactive map with the latest available data on COVID-19 (worldwide). [Read more »](#)

Vaccine tracker: Real time data on national vaccine doses distribution and vaccine update within EU/EEA countries. [Read more »](#)

Maps in support of the Council Recommendation on a coordinated approach to the restriction of free movement in response to the COVID-19 pandemic in the EU/EEA. These maps are published every Thursday based on a number of different indicators. [Read more »](#)

Response Measures Database of ECDC and the Joint Research Centre (JRC) of the European Commission is a regularly updated archive of non-pharmaceutical interventions introduced by 30 countries in the EU/EEA. [Read more »](#)

Updates on SARS-CoV-2 variants

SARS-CoV-2 variants of concern: Overview of the different variants that are currently being considered of concern and of interest as assessed by ECDC. [Read more »](#)

Variants of concern. The ECDC country overview includes an own section on variants of concern. It includes e.g. a map of sequencing volume, variant data table and weekly variant distribution by country. [Read more »](#)

Dashboard on SARS-CoV-2 variants. This dashboard provides an overview of the proportion of variants of concern and variants of interest in EU/EEA Member States together with sequencing volumes and complements the ECDC country overview report. [Read more »](#)

Download data on COVID-19

Much of ECDC's data can be downloaded from its website. This for instance includes, but is not limited to, reported number of cases and deaths, 14-day case notification rates, ICU and hospital admissions/occupancy, testing rates/positivity, vaccination data and response measures implemented in EU/EEA countries. [Link to downloadable data»](#)

Infographics, Videos, Webinars and more

Infographics and leaflets about COVID-19 – Infographics, leaflets and posters on COVID-19. [Read more »](#)

Videos on COVID-19 – What do we know about the COVID-19. [Read more »](#)

ECDC Virtual Academy (EVA) – COVID-19 Micro learning for public health professionals. [Read more »](#)

Other ECDC Outputs

ECDC website on COVID-19 – [Read more »](#)

ECDC surveillance definitions for COVID-19. [Read more »](#)

Find the latest evidence on:

- [Coronaviruses](#)
- [Risk factors and risk groups](#)
- [Transmission of COVID-19](#)
- [COVID-19 infection](#)
- [Clinical characteristics of COVID-19](#)
- [Diagnostic testing and screening for SARS-CoV-2](#)
- [Immune responses and immunity to SARS-CoV-2](#)
- [Treatment and pharmaceutical prophylaxis](#)
- [COVID-19 vaccines](#)

Surveillance definitions for COVID-19. High risk exposure/close contact, transmission status, death due to COVID-19. [Read more »](#)

Prevention and control of COVID-19 – how to protect yourself, risk groups, COVID-19 vaccination, patient and case management. [Read more »](#)

Q & A on COVID-19 aimed at public and lay audience – Questions and answers. [Read more »](#)

Recent peer-reviewed publications

Disclaimer: In view of the large number of COVID-19 related publications, this list is compiled based on a rapid review of titles and abstracts and subjective selection of peer-reviewed articles and does not include an additional qualitative assessment or critical appraisal of the evidence by ECDC.

1. Reopening strategies, mobility and COVID-19 infections in Europe: panel data analysis *BMJ*
Open [Read more »](#)
2. Syndromic surveillance: A key component of population health monitoring during the first wave of the COVID-19 outbreak in France, February-June 2020 *PLoS One* [Read more »](#)

3. Modelling the impact of reopening schools in the UK in early 2021 in the presence of the alpha variant and with roll-out of vaccination against SARS-CoV-2 *J Math Anal Appl* [Read more »](#)
4. Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis *Lancet Infect Dis* [Read more »](#)
5. Do COVID-19 containment measures work? Evidence from Switzerland *Swiss J Econ Stat* [Read more »](#)
6. Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance *JAMA* [Read more »](#)
7. Attitude toward a mandatory COVID-19 vaccination policy and its determinants: Evidence from serial cross-sectional surveys conducted throughout the pandemic in Germany *Vaccine* [Read more »](#)
8. First cases of Omicron in France are exhibiting mild symptoms, November 2021-January 2022 *Infect Dis Now* [Read more »](#)
9. A Comparative Analysis of In-Hospital Mortality per Disease Groups in Germany Before and During the COVID-19 Pandemic From 2016 to 2020 *JAMA Netw Open* [Read more »](#)
10. SARS-CoV-2 infections and hospitalisations among immigrants in Norway-significance of occupation, household crowding, education, household income and medical risk: a nationwide register study *Scand J Public Health* [Read more »](#)
11. Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study *Lancet Child Adolesc Health* [Read more »](#)
12. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron *Cell* [Read more »](#)
13. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection *Science Translational Medicine* [Read more »](#)
14. The effect of gestational age at BNT162b2 mRNA vaccination on maternal and neonatal SARS-CoV-2 antibody levels *Clin Infect Dis* [Read more »](#)
15. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCOVER): an interim report from a prospective observational cohort study *Lancet Healthy Longev* [Read more »](#)
16. Individual prevention and containment measures in schools in Catalonia, Spain, and community transmission of SARS-CoV-2 after school re-opening *PLoS One* [Read more »](#)
17. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection *N Engl J Med* [Read more »](#)
18. Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19 *N Engl J Med* [Read more »](#)
19. Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States *Front Public Health* [Read more »](#)
20. Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada *JAMA* [Read more »](#)
21. Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study *Clin Infect Dis* [Read more »](#)
22. Effectiveness of contact tracing in the control of infectious diseases: a systematic review *Lancet Public Health* [Read more »](#)
23. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression *Lancet* [Read more »](#)
24. First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales *PLoS Med* [Read more »](#)
25. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England *PLoS Med* [Read more »](#)
26. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries *Pharmacoepidemiol Drug Saf* [Read more »](#)

Additional Resources

Information from European Institutions, International Organisations and Centres for Disease Control and Prevention

European Union. Re-open EU: interactive tool with country information for travel and transportation [Read more »](#)

European Commission. Coronavirus response. [Read more »](#)

European Parliament. The EU's response to the coronavirus. [Read more »](#)

EU Healthy Gateways: [Published guidance and reports for COVID-19](#)

European Agency for Safety and Health (OSHA). COVID-19: Resources for the workplace: EU guidance, telework, resources from EU and international organisations. [Read more »](#)

European Food Safety Authority (EFSA). COVID-19. [Read more »](#)

European Medicines Agency (EMA): Treatments and vaccines for COVID-19. [Latest updates on COVID-19.](#)

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). COVID-19 and drugs. [Read more »](#)

Health Systems Response Monitor: [COVID-19 Health System Response Monitor](#) designed in response to the COVID-19 outbreak to collect and organize up-to-date information on how countries are responding to the crisis

World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. [Read more »](#)

Food and Agriculture Organization of the UN (FAO): Novel Coronavirus. [Read more »](#)

African Centres of Disease Control and Prevention. [Read more »](#)

Public Health Agency of Canada. [Read more »](#)

Chinese Center for Disease Control and Prevention. [Read more »](#)

Israel Center for Disease Control, Ministry of Health. [Read more »](#)

Korea Disease Control and Prevention Agency. [Read more »](#)

Ministry of Health of Mexico. [Read more »](#)

UK Health Security Agency. [Read more »](#)

US Centers for Disease Control and Prevention. [Read more »](#)

COVID-19 information pages of EU/EEA Member States



[Austria »](#)
[Belgium »](#)
[Bulgaria »](#)
[Croatia »](#)
[Cyprus »](#)
[Czechia »](#)
[Denmark »](#)
[Estonia »](#)
[Finland »](#)
[France »](#)



[Germany »](#)
[Greece »](#)
[Hungary »](#)
[Iceland »](#)
[Ireland »](#)
[Italy »](#)
[Latvia »](#)
[Liechtenstein »](#)
[Lithuania »](#)
[Luxembourg »](#)



[Malta »](#)
[Netherlands »](#)
[Norway »](#)
[Poland »](#)
[Portugal »](#)
[Romania »](#)
[Slovakia »](#)
[Slovenia »](#)
[Spain »](#)
[Sweden »](#)

Living Evidence Summaries

COAP: [COVID-19 Open Access Project](#) from the Institute of Social and Preventive Medicine ([ISPM](#)). This database is

updated daily with published articles from Pubmed and EMBASE and with preprints from medRxiv and bioRxiv.

COVID-END McMaster Health Forum: [living evidence syntheses](#) on a variety of topics including efficacy and effectiveness of COVID-19 vaccines in the presence of variants of concern (VOCs).

EPPI Centre: [COVID-19](#): a living systematic map of the evidence. Up-to-date map of the current evidence that are partitioned into broad domains for easy exploration.

MAGIC project (MAGIC Evidence Ecosystem Foundation, theBMJ, WHO): [Drug treatments for COVID-19](#) living systematic review and network meta-analysis and a [living WHO guideline on drugs for COVID-19](#)

NMA initiative: [COVID-19 – living initiative](#). Living mapping and living systematic review of Covid-19 trials.

PregCOV-19LSR by the University of Birmingham. Series of living systematic reviews (LSR) involving pregnant and postnatal women at risk, suspected, and diagnosed to have COVID-19 according to recommended methods. [Read more »](#)

WHO: [Living WHO guideline on drugs for COVID-19](#) (published by theBMJ)

Science Updates

Centre for Evidence-Based Medicine CEBM: [Oxford COVID-19 Evidence Service](#). Rapid reviews of primary care questions relating to COVID-19.

Cochrane: [Cochrane Reviews](#) and related content from the Cochrane Library relating to the COVID-19 pandemic.

COVID Reference International: Every day the “Top 10 scientific COVID-19 papers of the day” are presented. Also provides multiple other useful links to literature. [Read more »](#)

Evidence Aid: [Evidence Collection](#) on Coronavirus (COVID-19). This evidence collection contains plain-language summaries of high-quality research which are available in English, and translated into French, Spanish, Portuguese, Arabic and Chinese (simplified and traditional).

Health Information and Quality Authority Ireland: [COVID-19 Publications](#): Clinical evidence summaries and rapid reviews on various topics.

LitCovid: [curated literature hub](#) for tracking up-to-date scientific information about COVID-19. It is the most comprehensive resource on the subject, providing a central access a large number of relevant articles in PubMed.

US Centers for Disease Control and Prevention: [COVID-19 Science Updates](#) providing brief summaries of new COVID-19-related studies on many topics, including epidemiology, clinical treatment and management, laboratory science, and modeling. The summaries are released every Tuesday and Friday.

VA-ESP COVID-19 Reviews: [U.S. Veterans' Affairs \(VA\) Evidence Synthesis Program](#) - Inventory of living systematic reviews and 'rapid reviews', with a flag for living reviews and for reviews meeting minimum quality standards

Wolters Kluwer: [Clinical effectiveness COVID-19 Resources Available to All](#). View a categorized collection of all UpToDate COVID-19 content including clinical topics, algorithms, patient education and society guideline links.

World Health Organization: [COVID-19 Global literature on coronavirus disease](#). Literature database.